natgillin/translations-raw huggingface dataset:
The compound for use according to claim 4, wherein said salt is characterised by an XRDP as depicted in Figure 3. 
Spoj za uporabu prema zahtjevu 4, gdje je ta sol, naznačena XRDP-om kako je prikazan na Slici 3.
The compound for use according to any of claims 1-7 provided it is not the free base of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine in a non-crystalline form. 
Spoj za uporabu prema bilo kojem od zahtjeva 1-7 uz uvjet da to nije slobodna baza 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina u ne-kristaličnom obliku.
The compound for use according to any of claims 1-8 for use in the treatment of a patient who has previously received medication for the treatment of said disease which medication was ceased or reduced due to sleep or sexually related adverse events. 
Spoj za uporabu prema bilo kojem od zahtjeva 1-8 za uporabu u liječenju bolesnika koji je prethodno dobivao lijek za liječenje navedene bolesti, a koji lijek je prekinut ili mu je smanjena doza zbog neželjenih dodagađaja vezanih uz san ili seksualnost.
forming a compound of formula (I) by performing a ring closure reaction of a compound of formula (II) followed by reduction of the resulting imine (IIA): 
formiranje spoja formule (I) provođenjem reakcije zatvaranja prstena spoja formule (II) nakon čega slijedi redukcija dobivenog imina (IIA):
The deuterated benzopyran compound or pharmaceutically acceptable salt according to claim 1, characterized in that the compound is selected from: 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 1, naznačeno time što je spoj izabran od:
The deuterated benzopyran compound or pharmaceutically acceptable salt according to claim 2, characterized in that the compound is 6-(methyl-D3)-2-(trifluoromethyl)- 2H -chromene-3-carboxylic acid or a salt thereof. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačeno time što je spoj 6-(metil-D3)-2-(trifluorometil)-2H-kromen-3-karboksilna kiselina ili njegova sol.
The deuterated benzopyran compound or pharmaceutically acceptable salt according to claim 2, characterized in that the compound is 8-(ethyl-D5)-6-(trifluoromethoxy)-2-(trifluoromethyl)- 2H- chromene-3-carboxylic acid or a salt thereof. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačeno time što je spoj 8-(etil-D5)-6-(trifluorometoksi)-2-(trifluorometil)-2H-kromen-3-karboksilna kiselina ili njegova sol.
The deuterated benzopyran compound or pharmaceutically acceptable salt according to claim 2, characterized in that the compound is 6-chloro-5,7-(dimethyl-D6)-2-(trifluoromethyl)- 2H -chromene-3-carboxylic acid or a salt thereof. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačeno time što je spoj 6-kloro-5,7-(dimetil-D6)-2-(trifluorometil)-2H-kromen-3-karboksilna kiselina ili njegova sol.
The deuterated benzopyran compound or pharmaceutically acceptable salt according to claim 2, characterized in that the compound is 6-bromo-5,7-(dimethyl-D6)-2-(trifluoromethyl)- 2H -chromene-3-carboxylic acid or a salt thereof. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačeno time što je spoj 6-bromo-5,7-(dimetil-D6)--2-(trifluorometil)-2H-kromen-3-karboksilna kiselina ili njegova sol.
The deuterated benzopyran compound or pharmaceutically acceptable salt according to claim 2, characterized in that the compound is 8-chloro-6-(methyl-D3)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid or a salt thereof. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačeno time što je spoj 8-kloro-6-(metil-D3)-2-(trifluorometil)-2H-kromen-3-karboksilna kiselina ili njegova sol.
The deuterated benzopyran compound or pharmaceutically acceptable salt according to claim 2, characterized in that the compound is 6-bromo-8-(methyl-D3)-2-(trifluoromethyl)- 2H -chromene-3-carboxylic acid. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačeno time što je spoj 6-bromo-8-(metil-D3)-2-(trifluorometil)-2H-kromen-3-karboksilna kiselina.
The deuterated benzopyran compound or pharmaceutically acceptable salt according to claim 2, characterized in that the compound is 6,8-dibromo-5,7-(dimethyl-D6)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid or a salt thereof. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačeno time što je spoj 6,8-dibromo-5,7-(dimetil -D6)-2-(trifluorometil)-2H-kromen-3-karboksilna kiselina ili njegova sol.
The deuterated benzopyran compound or pharmaceutically acceptable salt according to any one of the preceding claims for use in preparing anti-inflammatory and analgesic drugs or preparing drugs for preventing or treating tumors. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema bilo kojem od prethodno navedenih patentnih zahtjeva za upotrebu u pripremi antiinflamatornih i analgetičkih lijekova ili pripremi lijekova za prevenciju ili liječenje tumora.
The deuterated benzopyran compound or pharmaceutically acceptable salt according to any one of the preceding claims for use in the treatment of inflammation characterized by rheumatoid arthritis, gouty arthritis, osteoarthritis and rachitis; or by one of systemic lupus erythematosus, psoriasis, eczema, skin inflammation and postpartum inflammation, bowel disease, gastritis, irritable bowel syndrome, headache, exarteritis, thyroiditis, aplastic anemia, retinitis, conjunctivitis, retinopathy, uveitis, hemeralopia, acute ocular tissue injury, viral infection and cystic fibrosis, allergic rhinitis, postpartum pain, toothache, muscle pain, cancer pain, aneurysm, coronary plaque inflammation, inflammation caused by bacteria, inflammation caused by viruses, inflammation caused by surgery, ocular vascular hyperplasia, retinal vascular hyperplasia, and gastric ulcer. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema bilo kojem od prethodno navedenih patentnih zahtjeva za upotrebu u liječenju inflamacije naznačene reumatoidnim artritisom, gihtom, osteoartritisom i rahitisom, ili podrazumjeva jedan sistemski eritemski lupus, psorijazu, ekcem, inflamaciju kože i postpartalnu inflamaciju, bolesti crijeva, gastritis, sindrom iritabilnog crijeva, glavobolju, periarteritis, tiroiditis, aplastičnu anemiju, retinitis, konjuktivitis, retinopatije, uveitis, hemeralopiju, akutnu očnu povredu tkiva, virusne infekcije i cistične fibroze, alergijski rinitis, postpartalni bol, zubobolju, mišićinu bol, bol uslijed kancerogenog oboljenja, aneurizmu, koronarnu plak inflamaciju, inflamaciju uzrokovanu bakterijama, inflamaciju uzrokovanu virusima, inflamaciju uzrokovanu kirurški, okularnu vaskularnu hiperplaziju, retinalnu vaskularnu hiperplaziju i peptički ulkus.
a domain from a Mycobacterium polypeptide, which is antigen (Ag) 85B or Ag85A, which is capable of eliciting an immune response, and 
domenu iz polipeptida mikobakterije, koja je antigen (Ag) 85B ili Ag85A, koja može potaknuti imuni odgovor, i
The cell of any one of claims 1-3 for the use of claim 1 for generating a Th17 immune response in a Mycobacterium-naïve subject or a subject pre-exposed to Mycobacterium challenge. 
Stanica iz bilo kojeg od patentnih zahtjeva 1-3 za uporabu iz patentnog zahtjeva 1 za stvaranje Th17 imunog odgovora u subjekta koji nije bio u dodiru s mikobakterijom ili subjekta prethodno izloženog mikobakteriji.
a domain from a Mycobacterium polypeptide, which is Ag85B or Ag85A which is capable of eliciting an immune response, and 
domenu iz polipeptida mikobakterije, koja je Ag85B ili Ag85A, koja može potaknuti imuni odgovor, i
A pharmaceutical composition comprising an effective amount of the compound: or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and further comprising an effective amount of an anti-HIV agent selected from the group consisting of HIV antiviral agents, immunomodulators and anti-infective agents. 
Farmaceutski pripravak koji sadrži efikasnu količinu spoja: [image] ili njegove farmaceutski prihvatljive soli i farmaceutski prihvatljiv nosač i dalje sadrži efikasnu količinu anti-HIV sredstva izabranog iz grupe koja se sastoji od HIV antivirusnih sredstava, imunomodulatora i anti-infektivnih sredstava.
The pharmaceutical composition according to claim 1, wherein the anti-HIV agent is an antiviral selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors. 
Farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time što anti-HIV sredstvo je antivirusno sredstvo izabrano iz grupe koja se sastoji od inhibitora HIV proteaze, inhibitora HIV integraze, ne-nukleozidnih inhibitora HIV reverzne transkriptaze, nukleozidnih inhibitora HIV reverzne transkriptaze, inhibitora fuzije HIV-a i inhibitora ulaska HIV-a.
The pharmaceutical composition according to claim 2, wherein the anti-HIV agent is one or more HIV antiviral selected from: abacavir, abacavir +lamivudine, 
Farmaceutski pripravak prema patentnom zahtjevu 2, naznačen time što je anti-HIV sredstvo jedno ili više od HIV antivirusnih sredstava izabranih od slijedećih:
tipranavir, vicriviroc The pharmaceutical composition according to claim 3, wherein the anti HIV agent is one or more HIV antiviral selected from lamivudine and tenofovir disoproxil fumarate. 
Farmaceutski pripravak prema patentnom zahtjevu 3, naznačen time što je anti-HIV sredstvo jedno ili više od HIV antivirusnih sredstava izabranih od lamivudina i tenofovir dizoproksil fumarata.
Use of a pharmaceutical composition according to any one of claims 1-6 for the manufacture of a medicament for the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS in a subject in need thereof. 
Uporaba farmaceutskog pripravka prema bilo kojem od patentnih zahtjeva 1-6 za proizvodnju lijeka za profilaksu ili liječenje infekcije HIV-om ili za profilaksu, liječenje ili odgađanje početka SIDA-e kod subjekta kod kojeg postoji potreba za istim.
A degradable, multi-layered gastroretentive drug formulation for the sustained release of an active agent in the stomach and gastrointestinal tract of a patient, comprising: 
Razgradiv, višeslojni oblik lijeka koji se zadržava u želucu zbog produženog otpuštanja aktivne tvari u želucu i probavnom sustavu pacijenta, obuhvaća:
the membrane being directly secured to and covering both sides of the internal layer and having a predetermined length greater than 20 mm in a planar orientation, the membrane and internal layer being arranged in an accordion folded orientation sufficiently compact to be placed within a capsule dissolvable within the stomach; 
membrana je izravno osigurana i prekriva obje strane unutarnjeg sloja i ima predodređenu duljinu veću od 20 mm u orijentaciji ravnine, membrana i unutarnji sloj su postavljeni u višeslojnom harmonika-obliku, dovoljno kompaktno za postavljanje unutar kapsule koja je topljiva u želucu;
the membrane and internal layer developing sufficient mechanical force to unfold from the initial accordion folded orientation to a length of at least 20 mm within 30 minutes of being exposed to gastric medium; 
membrana i unutarnji sloj razvijaju dovoljno mehaničke sile za odmotavanje od početnog višeslojnog oblika harmonike do duljine od najmanje 20 mm unutar 30 minuta od izlaganja želučanom mediju;
the membrane permitting passage of gastric media from the environment to the internal layer and permitting passage of the active agent from the internal layer through the membrane to the environment; 
membrana dozvoljava prolazak želučanog medija iz okoline do unutarnjeg sloja i dozvoljava prolaz aktivnoj tvari iz unutarnjeg sloja kroz membranu u okoliš;
The gastroretentive drug formulation of claim 5, where the formulation contains 375 mg of levodopa and 50 mg of carbidopa. 
Oblik lijeka koji se zadržava u želucu iz patentnog zahtjeva 5, pri čemu formulacija sadrži 375 mg levodopa i 50 mg karbidopa.
The gastroretentive drug formulation of claim 6, wherein 70 mg of the levodopa and 25 mg carbidopa are formulated as an immediate release component, whereas the rest of the carbidopa and the levodopa are released in a controlled manner over 8-10 hours. 
Oblik lijeka koji se zadržava u želucu iz patentnog zahtjeva 6, pri čemu su 70 mg levodopa i 25 mg karbidopa oblikovani kao sastavnica koja se izravno otpušta, dok se ostatak karbidopa i levodopa otpušta kontrolirano kroz 8-10 sati.
The gastroretentive drug formulation of claim 8, wherein 100 mg of the levodopa and 25 mg carbidopa are formulated as an immediate release component, and wherein the rest of the carbidopa and the levodopa are released in a controlled manner over 8-10 hours. 
Oblik lijeka koji se zadržava u želucu iz patentnog zahtjeva 8, pri čemu su 100 mg levodopa i 25 mg karbidopa oblikovani kao sastavnica koja se izravno otpušta, dok se ostatak karbidopa i levodopa otpušta kontrolirano kroz 8-10 sati.
A modular antibody according to claim 8, wherein the protein fused to the modular antibody is selected from the group consisting of other modular antibodies, immunoglobulins, ligands, scaffold proteins, enzymes, and toxins. 
Modularno antitijelo prema patentnom zahtjevu 8, gdje je protein fuzioniran za modularno antitijelo odabran iz grupe koja se sastoji od drugih modularnih antitijela, imunoglobulina, laganada, proteina skele (“scaffold”), enzima, i toksina.
The crystal according to claim 2 or 3, having peaks at angle 2θ of approximately 8.11, 8.43, 14.20, 14.67, 14.91 and 23.21 degrees in a powder x-ray diffraction spectrum. 
Kristal prema patentnom zahtjevu 2 ili 3, ima vrhove pod kutom od 2θ od približno 8.11, 8.43, 14.20, 14.67, 14.91 i 23.21 stupnjeva u spektru difrakcije X-zraka na prahu.
The pharmaceutical composition according to claim 11, wherein the Btk-related disease is an allergic disease, an autoimmune disease, an inflammatory disease, a thromboembolic disease, a bone-related disease, or cancer. 
Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 9, gdje Btk bolest je alergijska bolest, autoimuna bolest, inflamatorna bolest, tromboembolijska bolest, bolest povezana sa kostima, ili rak.
the fatty acid composition of the lipid comprises linoleic acid and alpha-linolenic acid in a weight ratio of 2 to 10, ii) the fatty acid composition of the lipid comprises at least 10 wt.% palmitic acid based on total fatty acids, and at least 15 wt.% of the palmitic acid is esterified to the sn-2 position of a triglyceride based on total palmitic acid, 
sastav masnih kiselina unutar lipida obuhvaća linolensku kiselinu i alfa-linolensku kiselinu u težinskom omjeru od 2 do 10, ii) sastav masnih kiselina unutar lipida obuhvaća barem 10 tež.% palmitinske kiseline u odnosu na ukupne masne kiseline, i barem 30 tež.% te ukupne palmitinske kiseline je esterificirano na sn-2 položaju triglicerida iii) lipidne globule imaju volumni modalni promjer od 1.0 µm ili veći, i gdje nutritivni pripravak nije humano mlijeko.
iii) the lipid globules are at least partly coated on the surface with phospholipids, the amount of phospholipids present in the nutritional composition being from 0.5 to 20 wt.% phospholipids based on total lipid, wherein the nutritional composition is not human milk. 
Nutritivni pripravak prema bilo kojem od prethodnih zahtjeva gdje su lipidne globule barem djelomično obložene fosfolipidima na površini, količina fosfolipida prisutnih u nutritivnom pripravku je od 0.5 do 20 tež.% fosfolipida u odnosu na ukupne lipide.
Nutritional composition according to any one of claims 1-13 for use in improving body composition, the improvement of body composition being selected from the group consisting of increased lean body mass, decreased fat mass relative to total body weight, decreased visceral fat mass relative to total body weight, a decreased visceral fat mass relative to total fat mass, decreased fat accumulation and increased muscle mass, increased bone mass and increased bone mineral density. 
Nutritivni pripravak prema bilo kojem od zahtjeva 1-13 za uporabu u poboljšanju tjelesne građe, poboljšanje tjelesne građe se odabire iz skupine koju čine povećanje nemasnog dijela tjelesne težine, smanjenje masne težine u odnosu na ukupnu tjelesnu težinu, smanjenje tkivne masne težine tkiva u odnosu na ukupnu tjelesnu težinu, smanjenje tkivne masne težine tkiva u odnosu na ukupnu masnu težinu, smanjenje nakupljanja masti fi povećanje mišićne mase, povećanje koštane mase i povećanje mineralne gustoće kostiju.
A quinazoline derivative which is NRC-2694, or a pharmaceutically acceptable salt thereof, for use in the treatment of brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, breast cancer, oesophageal cancer or thyroid cancer: 
Derivat kinazolina koji je NRC-2694 ili njegova farmaceutski prihvatljiva sol, za primjenu u liječenju karcinoma mozga, raka pluća, karcinoma pločastih stanica, raka mokraćnog mjehura, raka želuca, raka dojke, raka jednjaka ili raka štitnjače:
A quinazoline derivative according to claim 1, for use in the treatment of lung cancer, squamous cell cancer, or breast cancer. 
[image] Derivat kinazolina prema zahtjevu 1, za primjenu u liječenju raka pluća, karcinoma pločastih stanica ili raka dojke.
The multithreaded processor of claim 1, wherein the interrupt module is further configured to determine the interrupt priority is higher than the lowest priority. 
Višenitni procesor iz zahtjeva 1, pri čemu je modul prekida konfiguriran da odredi kako je prioritet prekida viši od najnižeg prioriteta.
The multithreaded processor of claim 1, wherein the priority encoder is further configured to identify one or more threads of the plurality of threads in wait mode and provide an indication of one or more threads in the wait mode as the indication of the lowest priority thread to the interrupt module. 
Višenitni procesor iz zahtjeva 1, pri čemu je prioritet za kodiranje nadalje konfiguriran da identificira jednu ili više niti između više niti u načinu čekanja i pruži indikaciju jedne ili više niti u načinu čekanja kao indikaciju niti najnižeg prioriteta modulu prekida.
The multithreaded processor of claim 1, wherein the priority encoder is configured to identify one of the plurality of threads in wait mode based on the priority of the plurality of threads. 
Višenitni procesor iz zahtjeva 1, pri čemu je prioritet za kodiranje konfiguriran da identificira jednu od više niti u načinu čekanja temeljem prioriteta više niti.
The multithreaded processor of claim 1, wherein the multithreaded processor is disposed in a portable communication device. 
Višenitni procesor iz zahtjeva 1, pri čemu je višenitni procesor smješten u prijenosnom komunikacijskom uređaju.
a second register configured to store a second thread priority corresponding to the second priority. 
i drugi registar konfiguriran za pohranu drugog prioriteta niti koji odgovara drugom prioritetu.
The processor unit of claim 7, wherein the interrupt module is configured to: 
Procesorska jedinica iz zahtjeva 7, pri čemu je modul prekida konfiguriran da:
The processor unit of claim 7, wherein the execution module comprises a third thread configured in a wait mode and a third register configured to store a third thread priority indicating the wait mode; and wherein the priority encoder is further configured to identify the third thread in wait mode and provide an indication of the third thread as the indication of the lowest priority thread to the interrupt module. 
Procesorska jedinica iz zahtjeva 7, pri čemu modul za izvršenje obuhvaća treću nit konfiguriranu u načinu čekanja i treći registra konfiguriran za pohranu prioriteta treće niti koji započinje način čekanja; i pri čemu je prioritet za kodiranje nadalje konfiguriran da identificira treću nit u načinu čekanja i pruži indikaciju niti najnižeg prioriteta modulu prekida. Postupak obuhvaća:
executing (404) a first task on a first thread; 
izvršavanje (404) prvog zadatka na prvoj niti;
executing (404) a second task on a second thread; 
izvršavanje (404) drugog zadatka na drugoj niti;
The wall panel according to claim 1, wherein said insulating layer (45, 50) is formed as a multi-layer structure comprising an inner layer (45) of acoustic damping material and/or fire resistant material, optionally heat insulation material, and an outer layer, preferably of gypsum board (43). 
Zidna ploča sukladno zahtjevu 1, pri čemu je izolacijski sloj (45, 50) formiran kao višeslojna struktura koja obuhvaća unutarnji sloj (45) akustičnog materijala za prigušivanje i/ili vatrootpornog materijala, opcionalno materijala toplinskog izolatora, i vanjski sloj, poželjno od gips ploče (43).
The wall panel according to claim 2, wherein said panel (4) is substantially symmetrical along the wooden core element (41). 
Zidna ploča sukladno zahtjevu 2, pri čemu je ploča (4) supstancijalno simetrična duž drvenog središnjeg elementa (41).
is a member selected from the group consisting of hydrogen, halo and C1-C6 alkyl; V is a member selected from the group consisting of oxygen and a single bond; 
je član odabran iz skupine koju čine vodik, halogen i C1-C6 alkil; V je član odabran iz skupine koja se sastoji od kisika i jednostruke veze;
Ra is a member independently selected from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl and (C1-C4 alkyl)carbonyl, wherein alkyl and cycloalkyl groups or portions are optionally partly or completely fluorinated; 
Ra je član neovisno odabran iz skupine koja se sastoji od H, C1-C6 alkila, C3-C6cikloalkila te (C1-C4 alkil)karbonila, pri čemu su alkilne i cikloalkilne skupine ili dijelovi po želji djelomično ili potpuno fluorirani;
A method in accordance with claim 1, wherein said reducing agent is an alkylsilyl hydride and the activating agent is a Lewis acid. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je navedeno sredstvo za reduciranje alkilsililni hidrid, a aktivirajući agens je Lewisova kiselina.
A method in accordance with claim 4, wherein said reducing agent is triethylsilane and said Lewis acid is BF3·Et2O. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time, da je navedeno sredstvo za reduciranje trietilsilan, a navedena Lewisova kiselina je BF3-Et20.
A method in accordance with claim 1, wherein step (a) is carried out in a solvent or solvent mixture comprising a member selected from the group consisting of acetonitrile and dichloromethane. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se korak (a) provodi u otapalu ili smjesi otapala koje sadržava član odabran iz skupine koja se sastoji od acetonitrila i diklormetana.
A method in accordance with claim 1, wherein step (b) is carried out in a solvent or solvent mixture comprising a member selected from the group consisting of ethanol, water and hexane. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se korak (b) provodi u otapalu ili smjesi otapala koje sadržava član odabran iz skupine koja se sastoji od etanola, vode i heksana.
A method in accordance with any of claims 1 to 8 wherein said amino acid is selected from the group consisting of proline and phenylalanine. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time, da je navedena aminokiselina odabrana iz skupine koja se sastoji od prolina i fenilalanina.
A method in accordance with claim 9, wherein said amino acid is proline and the subscript n is 2. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time, da je aminokiselina prolin, a indeks n je 2.
A crystalline form in accordance with claim 12, characterized by 
Kristalni oblik u skladu s patentnim zahtjevom 12, naznačen time, da
an X-ray powder diffraction pattern that comprises peaks at 4.08, 6.04, 17.19, 19.86 and 21.12 degrees 2θ (± 0.05 degrees 2θ); or 
uzorak rendgenske difrakcije na prahu sadržava vršne vrijednosti na 4.08, 6.04, 17.19, 19.86 i 21.12 stupnjeva 26 (± 0.05 stupnjeva 29) ili